Flow Cytometry
Customize your policy alerts
Sign up for avalon_healthcare_solutions Policy AHS - F2019 - Flow Cytometry alerts
Get alerted when Policy AHS - F2019 - Flow Cytometry changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage and reimbursement limits for flow cytometry, including immunophenotyping, cell enumeration, and related laboratory testing. Coverage is subject to the member’s benefit plan and applicable Medicare, Medicaid, or other government policies.
Coverage criteria were expanded in 2022 to include myeloproliferative disorders within the covered hematologic indications.
Repetitive coverage criteria and CPT code 88199 were removed.
Routine flow cytometry-derived DNA content or cell proliferative activity for prognostic or therapeutic cancer management was added as noncovered.
Minimal residual disease testing was linked to Avalon Policy AHS M2175-Minimal Residual Disease (MRD).
Molar pregnancy screening was removed as a flow cytometry indication.
The policy clarified that CPT codes 88187, 88188, and 88189 must not be used together for a single specimen.
A reimbursement limitation was added allowing up to two specimens per day and reimbursing codes 88187, 88188, and 88189 at one unit per specimen.
The transplant-related indication was expanded to include both preoperative and postoperative monitoring.
The primary immunodeficiency indication was revised to state coverage for individuals with primary immunodeficiencies.
Reimbursement and code incompatibility language was clarified for the 2026 revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.